Apolipoprotein A1, Plasma
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Evaluation of risk for atherosclerotic disease
Detection of Tangier disease
Automated Turbidimetric Immunoassay
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Apolipoprotein A1, P
Apolipoprotein A1+B ORDER 80318
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
1. Fasting-overnight (12-14 hours).
2. Patient must not consume any alcohol for 24 hours before the specimen is drawn.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross OK
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Plasma EDTA||Refrigerated (preferred)||8 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Apolipoprotein AI (Apo AI) is 1 of the apoproteins of high-density lipoproteins (HDL). Plasma HDL cholesterol concentration is inversely related to the risk for coronary artery disease. Individuals with Tangier disease have <1% the normal amount of HDL and thus Apo AI.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
> or =18 years: 106-220 mg/dL
Reference values have not been established for patients that are less than 18 years of age.
Values less than approximately 90 mg/dL indicate increased risk for atherosclerotic disease.
Blood plasma of persons with Tangier disease contains no more than 1% of the Apolipoprotein AI present in normal plasma.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Fasting for <12 hours or intake of alcohol during the 24 hours prior to specimen collection may invalidate test results.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Franzen J, Fex G: Low serum apolipoprotein A-1 in acute myocardial infarction survivors with normal HDL cholesterol. Atherosclerosis 1986;59:37-42
2. Sniderman A, Shapiro S, Marpole D, et al: Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density [beta] lipoproteins]. Proceedings of the National Academy of Science USA 1980;77:604-608
Method Description Describes how the test is performed and provides a method-specific reference
Antibody to human Apolipoprotein AI (Apo AI) is added to a diluted aliquot of plasma or serum. The increase in light scatter resulting from the antigen-antibody reaction is measured and is a function of the concentration of Apo AI. A multi-point standard curve is used for calculation of Apo AI concentrations from the light scattering values. (Contois J, McNamara JR, Lammi-Keefe C, et al: Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:507-514)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; Continuous
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
1 day (not reported on Saturday or Sunday)
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|APLA1||Apolipoprotein A1, P||1869-7|